Home Cart Sign in  
Chemical Structure| 1687736-54-4 Chemical Structure| 1687736-54-4

Structure of SGC707
CAS No.: 1687736-54-4

Chemical Structure| 1687736-54-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SGC707 is a chemical probe of PRMT3 with IC50 of 31 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SGC707

CAS No. :1687736-54-4
Formula : C16H18N4O2
M.W : 298.34
SMILES Code : O=C(NCC(N1CCCC1)=O)NC2=CC3=C(C=NC=C3)C=C2
MDL No. :MFCD28411624
InChI Key :DMIDPTCQPIJYFE-UHFFFAOYSA-N
Pubchem ID :90642938

Safety of SGC707

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of SGC707

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 1.6 μM Stabilized PRMT3 with EC50 of 1.6 μM PMC4400258
HEK293 1.3 μM Stabilized PRMT3 with EC50 of 1.3 μM PMC4400258
MOLT4 cells 10 μM 24 hours Evaluate PRMT3 degradation effect, 11 significantly degraded PRMT3 protein PMC11481256
MOLM13 cells 10 μM 24 hours Evaluate PRMT3 degradation effect, 11 significantly degraded PRMT3 protein PMC11481256
MV-4-11 cells 10 μM 24 hours Evaluate PRMT3 degradation effect, 11 significantly degraded PRMT3 protein PMC11481256
RS4;11 cells 10 μM 24 hours Evaluate PRMT3 degradation effect, 11 significantly degraded PRMT3 protein PMC11481256
Huh7 cells 1 µM 48 hours Inhibited PRMT3-mediated LDHA methylation, reduced glucose consumption and lactate production PMC8797063
SNU398 cells 1 µM 48 hours Inhibited PRMT3-mediated LDHA methylation, reduced glucose consumption and lactate production PMC8797063
Human mesenchymal stem cells (hMSCs) 10 μM 96 hours SGC707 significantly inhibited the osteogenic differentiation ability of hMSCs, as evidenced by reduced ALP activity and calcium deposition. PMC6680051
HMO6 cells 10 μM No effect on normal brain cell growth PMC9646854
HEB cells 10 μM No effect on normal brain cell growth PMC9646854
GSC262 cells 10 μM Inhibited GSC cell growth PMC9646854
GSC28 cells 10 μM Inhibited GSC cell growth PMC9646854
U87 cells 10 μM Inhibited GBM cell growth PMC9646854
U251 cells 10 μM Inhibited GBM cell growth PMC9646854

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
LDL receptor knockout mice Atherogenic Western-type diet-fed model Intraperitoneal injection 0.3 mg per injection, approximately 10 mg/kg 3 times per week for 3 weeks To investigate the effect of SGC707 on hepatic steatosis and plasma triglyceride levels. Results showed that SGC707 treatment reduced liver triglyceride stores by 50% and plasma triglyceride levels by 32%, but induced pruritus and skin lesions. PMC8748717
NOG-dKO mice CDX and PDX models Intraperitoneal injection 10 mg/kg Every 2 days until the end of the study SGC707 combined with anti-PD-1 therapy showed more potent antitumor effects. PMC10754120
C57BL/6 mice Chronic kidney disease (CKD) model Intraperitoneal injection 10 mg/kg For 10 weeks To investigate the effect of SGC707 on vascular calcification in CKD mice. Results showed that SGC707 alleviated CKD-induced vascular calcification and renal injury. PMC10782741
C57BL/6 mice T0901317 and palm oil-induced hepatic steatosis model Intraperitoneal injection 10 or 30 mg/kg Three injections over 4 days To evaluate the effect of PRMT3 inhibition on LXR-mediated hepatic lipogenesis. Results showed that SGC707 treatment significantly reduced hepatic lipogenic gene expression and liver triglyceride content. PMC6031883
Mice Osteoporosis model Subcutaneous implantation of ALZET pump 20 mg/kg/day Continuous for 6 weeks SGC707 treatment resulted in bone loss in mice, characterized by reduced bone density and trabecular number. PMC6680051
Mice WT mice Intraperitoneal injection 30 mg/kg Single injection, 24 h before viral infection PRMT3 inhibitor (SGC707) treatment promotes antiviral innate immunity in vivo. PMC10483634
Nude mice GSC262 xenograft model Intraperitoneal injection 30 mg/kg Daily from day 21 to day 34 Inhibited tumor growth PMC9646854
BALB/C nude mice Subcutaneous xenograft model Intraperitoneal injection 30 mg/kg Every 2 days for approximately 30 days SGC707 treatment significantly inhibited PRMT3 overexpression-induced tumor growth PMC8797063

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.35mL

0.67mL

0.34mL

16.76mL

3.35mL

1.68mL

33.52mL

6.70mL

3.35mL

References

 

Historical Records

Categories